文献速递前列腺癌

18F-PSMA-1007 PET-CT 与常规影像在高危前列腺癌初始远处转移分期中的前瞻性比较(PROSTAGE)

A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).
PubMed 文献 · Eur Urol Oncol · 2020-07-13

PROSTAGE 为前瞻性单中心试验,纳入 80 例新诊断高危前列腺癌患者,比较骨扫描、CT、SPECT-CT、全身 MRI 与 18F-PSMA-1007 PET-CT 的初始远处转移分期效能。结果显示 PSMA PET-CT 对骨转移检测的 AUC 最高(0.90–0.91),并在 11/20 例标准影像阴性患者中检出转移,影响 18/79 例临床决策。

要点

  • 高危前列腺癌初始分期中,18F-PSMA-1007 PET-CT 对远处转移的检测效能优于传统影像。
  • PSMA PET-CT 在标准影像阴性的患者中额外检出 11/20 例转移,并影响 18% 患者的临床决策。
  • 需警惕 PSMA PET-CT 的骨病变假阳性(12/79 例仅由 PSMA PET-CT 报告)。

核心结论

  • 在高危前列腺癌初始远处转移分期中,18F-PSMA-1007 PET-CT 优于所有其他受试影像方法,但存在骨病变假阳性风险。

研究设计与样本

  • 前瞻性单中心试验(NCT03537391),纳入 80 例新诊断高危前列腺癌患者(ISUP grade group ≥3 和/或 PSA ≥20 和/或 cT ≥ T3),2018 年 3 月至 2019 年 6 月入组。
  • 患者于入组 2 周内无预设顺序接受骨扫描、CT、99mTc-HMDP SPECT-CT、1.5 T 全身 MRI(含弥散加权成像)和 18F-PSMA-1007 PET-CT 五种影像检查。
  • 以至少 12 个月临床随访所获全部信息定义参考标准诊断,对参考标准诊断不明确者追加 MRI 和/或 CT 寻找解剖对应。

主要发现

  • 79 例完成全部影像检查(1 例 MRI 中断),20 例(25%)检出转移性疾病。
  • 18F-PSMA-1007 PET-CT 敏感性最高且阅片者间一致性最高;骨转移检测 AUC 为读者1 0.90(95%CI 0.85–0.95)、读者2 0.91(95%CI 0.87–0.96)。
  • 骨扫描 AUC 为 0.71(95%CI 0.58–0.84)和 0.8(95%CI 0.67–0.92),CT 为 0.53(95%CI 0.39–0.67)和 0.66(95%CI 0.54–0.77),SPECT-CT 为 0.77(95%CI 0.65–0.89)和 0.75(95%CI 0.62–0.88),全身 MRI 为 0.85(95%CI 0.74–0.96)和 0.67(95%CI 0.54–0.80)。
  • 18F-PSMA-1007 PET-CT 在 11/20 例标准影像阴性患者中检出转移性疾病,并影响 14/79(18%)例患者的临床决策。
  • 12/79 例仅由 PSMA PET-CT 报告骨病变假阳性。

临床怎么用

  • 对高危前列腺癌初始分期,可优先考虑 18F-PSMA-1007 PET-CT 以提高远处转移检出率。
  • PSMA PET-CT 阴性不能完全排除转移,阳性骨病变需结合临床与随访影像警惕假阳性。
  • PSMA PET-CT 结果可能改变约 18% 高危患者的临床决策,应结合多学科讨论解读。

局限性

  • 非随机研究设计。
  • 经组织病理学验证的可疑病变数量少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Computed tomography (CT) and bone scintigraphy (BS) are the imaging modalities currently used for distant metastasis staging of prostate cancer (PCa). OBJECTIVE: To compare standard staging modalities with newer and potentially more accurate imaging modalities. DESIGN, SETTING, AND PARTICIPANTS: This prospective, single-centre trial (NCT03537391) enrolled 80 patients with newly diagnosed high-risk PCa (International Society of Urological Pathology grade group ≥3 and/or prostate-specific antigen [PSA] ≥20 and/or cT ≥ T3; March 2018-June 2019) to undergo primary metastasis staging with two standard and three advanced imaging modalities. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The participants underwent the following five imaging examinations within 2 wk of enrolment and without a prespecified sequence: BS, CT, 99mTc-hydroxymethylene diphosphonate (99mTc-HMDP) single-photon emission computed tomography (SPECT)-CT, 1.5 T whole-body magnetic resonance imaging (WBMRI) using diffusion-weighted imaging, and 18F-prostate-specific membrane antigen-1007 (18F-PSMA-1007) positron emission tomography(PET)-CT. Each modality was reviewed by two independent experts blinded to the results of the prior studies, who classified lesions as benign, equivocal, or malignant. Pessimistic and optimistic analyses were performed to resolve each equivocal diagnosis. The reference standard diagnosis was defined using all available information accrued during at least 12 mo of clinical follow-up. Patients with equivocal reference standard diagnoses underwent MRI and/or CT to search for the development of anatomical correspondence. PSMA PET-avid lesions without histopathological verification were rated to be malignant only if there was a corresponding anatomical finding suspicious for malignancy at the primary or follow-up imaging. RESULTS AND LIMITATIONS: Seventy-nine men underwent all imaging modalities except for one case of interrupted MRI. The median interval per patient between the first and the last imaging study was 8 d (interquartile range [IQR]: 6-9). The mean age was 70 yr (standard deviation: 7) and median PSA 12 ng/mL (IQR:7-23). The median follow-up was 435 d (IQR: 378-557). Metastatic disease was detected in 20 (25%) patients. The imaging modality 18F-PSMA-1007 PET-CT had superior sensitivity and highest inter-reader agreement. The area under the receiver-operating characteristic curve (AUC) values for bone metastasis detection with PSMA PET-CT were 0.90 (95% confidence interval [CI]: 0.85-0.95) and 0.91 (95% CI: 0.87-0.96) for readers 1 and 2, respectively, while the AUC values for BS, CT, SPECT-CT, and WBMRI were 0.71 (95% CI: 0.58-0.84) and 0.8 (95% CI: 0.67-0.92), 0.53 (95% CI: 0.39-0.67) and 0.66 (95% CI: 0.54-0.77), 0.77 (95% CI: 0.65-0.89) and 0.75 (95% CI: 0.62-0.88), and 0.85 (95% CI: 0.74-0.96) and 0.67 (95% CI: 0.54-0.80), respectively, for the other four pairs of readers. The imaging method 18F-PSMA-1007 PET-CT detected metastatic disease in 11/20 patients in whom standard imaging was negative and influenced clinical decision making in 14/79 (18%) patients. In 12/79 cases, false positive bone disease was reported only by PSMA PET-CT. Limitations included a nonrandomised study setting and few histopathologically validated suspicious lesions. CONCLUSIONS: Despite the risk of false positive bone lesions, 18F-PSMA-1007 PET-CT outperformed all other imaging methods studied for the detection of primary distant metastasis in high-risk PCa. PATIENT SUMMARY: In this report, we compared the diagnostic performance of conventional and advanced imaging. It was found that 18F-prostate-specific membrane antigen-1007 positron emission tomography/computed tomography (18F-PSMA-1007 PET-CT) was superior to the other imaging modalities studied for the detection of distant metastasis at the time of initial diagnosis of high-risk prostate cancer. PSMA PET-CT also appears to detect some nonmetastatic bone lesions.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Anttinen M, Ettala O, Malaspina S, et al. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur Urol Oncol. 2020. PMID: 32675047. doi:10.1016/j.euo.2020.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。